Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Diagnostics & Research

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing and sterile fill-finish services. It also provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.

Revenue projections:

Revenue projections for SYNGENE
Revenue projections for SYNGENE

Revenues for SYNGENE are expected to drop compared to the previous year, which could be a cause for concern for investors. A decline in earnings may negatively impact the company's profitability, leading cautious investors to reconsider their positions, as it often signals challenges in overall financial health.

Financial Ratios:

currentRatio 0.00000
forwardPE 37.11926
debtToEquity 12.28300
earningsGrowth -0.87400
revenueGrowth -0.02800
grossMargins 0.68297
operatingMargins 0.12943
trailingEps 8.76000
forwardEps 11.34721

SYNGENE's low Debt-to-Equity ratio reflects limited reliance on debt, signaling the company is not over-leveraged. This lower financial risk suggests that SYNGENE has a strong capital structure, which can help sustain long-term stability and attract cautious investors.
With both earnings and revenue growth in low territory, Syngene International Limited is likely to see shrinking profits. This signals a possible downturn in the company's financial health and may raise concerns about its future profitability.
SYNGENE's negative gross and operating margins indicate that the company is unable to generate profit from its core business activities. This suggests financial strain and could be a sign of deeper cost management issues.
Syngene International Limited's forward EPS is greater than its trailing EPS, indicating that the company is expected to deliver higher profitability this year. This suggests that Syngene International Limited is projected to improve its earnings, reflecting positive growth compared to last year's financial performance.

Price projections:

Price projections for SYNGENE
Price projections for SYNGENE

SYNGENE's price projections have been revised downward gradually, indicating that analysts are tempering their expectations. This downward shift suggests a more cautious outlook on the company's growth prospects.

Recommendation changes over time:

Recommendations trend for SYNGENE
Recommendations trend for SYNGENE


A recent buy bias from analysts toward SYNGENE indicates strong confidence in the stock's future performance. This could encourage investors to park their money in SYNGENE, viewing it as a stable and potentially rewarding investment opportunity with promising long-term growth prospects.